XOMA Royalty Corporation Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2024

Fair Value Measurements

Schedule of financial assets and liabilities measured at fair value on a recurring basis

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):


		Fair Value Measurements as of December 31, 2024 Using:
		Quoted Prices in			Significant Other			Significant
		Active Markets for			Observable			Unobservable
		Identical Assets			Inputs			Inputs
		(Level 1)			(Level 2)			(Level 3)			Total
Assets:
Cash equivalents:
Money market funds		$	72,304		$	—		$	—		$	72,304
U.S. treasury bills			20,367			—			—			20,367
Total cash equivalents			92,671			—			—			92,671
Exarafenib milestone asset (Note 4)			—			—			3,214			3,214
Investment in equity securities			3,529			—			—			3,529
Total financial assets		$	96,200		$	—		$	3,214		$	99,414
Liabilities:
Exarafenib milestone contingent consideration (Note 4)		$	—		$	—		$	3,214		$	3,214
Contingent consideration under RPAs, AAAs, and CPPAs, measured at fair value			—			—			—			—
Total financial liabilities		$	—		$	—		$	3,214		$	3,214


		Fair Value Measurements as of December 31, 2023 Using:
		Quoted Prices in			Significant Other			Significant
		Active Markets for			Observable			Unobservable
		Identical Assets			Inputs			Inputs
		(Level 1)			(Level 2)			(Level 3)			Total
Assets:
Cash equivalents:
Money market funds		$	28,352		$	—		$	—		$	28,352
Total cash equivalents			28,352			—			—			28,352
Investment in equity securities			161			—			—			161
Total financial assets		$	28,513		$	—		$	—		$	28,513
Liabilities:
Contingent consideration under RPAs, AAAs, and CPPAs, measured at fair value		$	—		$	—		$	1,000		$	1,000